Therapy of endocrine disease: Islet transplantation for type 1 diabetes: So close and yet so far away

European Journal of Endocrinology

Volumn 173, Issue 5, 2015, Pages R165-R183

  Khosravi Maharlooei, Mohsen ^a,g   Hajizadeh Saffar, Ensiyeh ^a   Tahamtani, Yaser ^a   Basiri, Mohsen ^a   Montazeri, Leila ^a   Khalooghi, Keynoosh ^a   Ashtiani, Mohammad Kazemi ^a   Farrokhi, Ali ^a,g   Aghdami, Nasser ^b   Hashemi Nejad, Anavasadat Sadr ^a   Larijani, Mohammad Bagher ^c   De Leu, Nico ^d   Heimberg, Harry ^d   Luo, Xunrong ^e   Baharvand, Hossein ^a,f  

^a Stem Cell Technology Research Center   (Iran)

^b ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d DIABETES RESEARCH CENTER   (Belgium)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF SCIENCE AND CULTURE   (Iran)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANOIKIS; APOPTOSIS; CELL ENCAPSULATION; CELL ISOLATION; CELL REGENERATION; CELL TRANSDIFFERENTIATION; CULTURE TECHNIQUE; DENDRITIC CELL; EMBRYONIC STEM CELL; ENGRAFTMENT; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSTANT BLOOD MEDIATED INFLAMMATORY REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE STRESS; OXYGEN SUPPLY; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TREATMENT OUTCOME; VASCULARIZATION; DIABETES MELLITUS, TYPE 1; STANDARDS;

DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION;

EID: 84946049498     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0094     Document Type: Review

References (193)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine 1993 329 977-986. (doi:10.1056/NEJM199309303291401)
2. Tavakoli A & Liong S. Pancreatic transplant in diabetes. Advances in Experimental Medicine and Biology 2012 771 420-437.
3. Najarian JS, Sutherland DE, Matas AJ, Steffes MW, Simmons RL & Goetz FC. Human islet transplantation: a preliminary report. Transplantation Proceedings 1977 9 233-236.
4. Ricordi C, Lacy PE & Scharp DW. Automated islet isolation from human pancreas. Diabetes 1989 38 (Suppl 1) 140-142. (doi:10.2337/diab.38.1.S140)
5. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM & Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine 2000 343 230-238. (doi:10.1056/NEJM200007273430401)
6. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001 50 710-719. (doi:10.2337/diabetes. 50.4.710)
7. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR & Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes 2005 54 2060-2069. (doi:10.2337/diabetes. 54.7.2060)
8. Hering BJ, Kandaswamy R, Harmon JV, Ansite JD, Clemmings SM, Sakai T, Paraskevas S, Eckman PM, Sageshima J, Nakano M et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. American Journal of Transplantation 2004 4 390-401. (doi:10.1046/j.1600-6143.2003. 00351.x)
9. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. Journal of the American Medical Association 2005 293 830-835. (doi:10.1001/jama.293.7.830)
10. Warnock GL, Meloche RM, Thompson D, Shapiro RJ, Fung M, Ao Z, Ho S, He Z, Dai LJ, Young L et al. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus. Archives of Surgery 2005 140 735-744. (doi:10.1001/archsurg.140.8.735)
11. Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, Johnson JD, Verchere CB, Partovi N, Begg IS et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008 86 1762-1766. (doi:10.1097/TP.0b013e318190b052)
12. Leitao CB, Tharavanij T, Cure P, Pileggi A, Baidal DA, Ricordi C & Alejandro R. Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care2008 31 2113-2115. (doi:10.2337/dc08-0741)
13. Tharavanij T, Betancourt A, Messinger S, Cure P, Leitao CB, Baidal DA, Froud T, Ricordi C & Alejandro R. Improved long-term health-related quality of life after islet transplantation. Transplantation 2008 86 1161-1167. (doi:10.1097/TP.0b013e31818a7f45)
14. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012 35 1436-1445. (doi:10.2337/dc12-0063)
15. Bellin MD, Barton FB, Heitman A, Harmon JV, Kandaswamy R, Balamurugan AN, Sutherland DE, Alejandro R & Hering BJ. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. American Journal of Transplantation 2012 12 1576-1583. (doi:10.1111/j.1600-6143.2011. 03977.x)
16. Markmann JF, Deng S, Desai NM, Huang X, Velidedeoglu E, Frank A, Liu C, Brayman KL, Lian MM, Wolf B et al. The use of non-heart-beating donors for isolated pancreatic islet transplantation. Transplantation 2003 75 1423-1429. (doi:10.1097/01.TP.0000061119. 32575.F4)
17. Dufrane D & Gianello P. Pig islet for xenotransplantation in human: structural and physiological compatibility for human clinical application. Transplantation Reviews 2012 26 183-188. (doi:10.1016/j.trre. 2011.07.004)
18. van der Windt DJ, Bottino R, Kumar G, Wijkstrom M, Hara H, Ezzelarab M, Ekser B, Phelps C, Murase N, Casu A et al. Clinical islet xenotransplantation: how close are we? Diabetes 2012 61 3046-3055. (doi:10.2337/db12-0033)
19. Van Hoof D, D'Amour KA & German MS. Derivation of insulin-producing cells from human embryonic stem cells. Stem Cell Research 2009 3 73-87. (doi:10.1016/j.scr.2009.08.003)
20. Pagliuca FW & Melton DA. How to make a functional b-cell. Development 2013 140 2472-2483. (doi:10.1242/dev.093187)
21. Miyazaki S, Yamato E & Miyazaki J. Regulated expression of pdx-1 promotes in vitro differentiation of insulin-producing cells from embryonic stem cells. Diabetes 2004 53 1030-1037. (doi:10.2337/diabetes.53.4.1030)
22. Xu H, Tsang KS, Chan JC, Yuan P, Fan R, Kaneto H & Xu G. The combined expression of Pdx1 and MafA with either Ngn3 or NeuroD improve the differentiation efficiency of mouse embryonic stem cells into insulin-producing cells. Cell Transplantation 2013 22 147-158. (doi:10.3727/096368912X653057)
23. Blyszczuk P, Czyz J, Kania G, Wagner M, Roll U, St-Onge L & Wobus AM. Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. PNAS 2003 100 998-1003. (doi:10.1073/pnas.0237371100)
24. Morris SA, Cahan P, Li H, Zhao AM, San Roman AK, Shivdasani RA, Collins JJ & Daley GQ. Dissecting engineered cell types and enhancing cell fate conversion via CellNet. Cell 2014 158 889-902. (doi:10.1016/j.cell.2014.07.021)
25. Xu Y, Shi Y & Ding S. A chemical approach to stem-cell biology and regenerative medicine. Nature 2008 453 338-344. (doi:10.1038/nature07042)
26. Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D & Melton DA. Generation of functional human pancreatic b cells in vitro. Cell 2014 159 428-439. (doi:10.1016/j.cell.2014.09.040)
27. Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O'Dwyer S, Quiskamp N, Mojibian M, Albrecht T et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nature Biotechnology 2014 32 1121-1133. (doi:10.1038/nbt.3033)
28. Schulz TC, Young HY, Agulnick AD, Babin MJ, Baetge EE, Bang AG, Bhoumik A, Cepa I, Cesario RM, Haakmeester C et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS ONE 2012 7 e37004. (doi:10.1371/journal. pone.0037004)
29. Rong Z, Wang M, Hu Z, Stradner M, Zhu S, Kong H, Yi H, Goldrath A, Yang YG, Xu Y et al. An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell 2014 14 121-130. (doi:10.1016/j.stem.2013.11.014)
30. Szot GL, Yadav M, Lang J, Kroon E, Kerr J, Kadoya K, Brandon EP, Baetge EE, Bour-Jordan H & Bluestone JA. Tolerance induction and reversal of diabetes in mice transplanted with human embryonic stem cell-derived pancreatic endoderm. Cell Stem Cell 2015 16 148-157. (doi:10.1016/j.stem.2014.12.001)
31. Yarborough M, Tempkin T, Nolta J & Joyce N. The complex ethics of first in human stem cell clinical trials. AJOB Neuroscience 2012 3 14-16. (doi:10.1080/21507740.2012.675010)
32. Zhang D, Jiang W, Liu M, Sui X, Yin X, Chen S, Shi Y & Deng H. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Research 2009 19 429-438. (doi:10.1038/cr.2009.28)
33. Zhao T, Zhang ZN, Rong Z & Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011 474 212-215. (doi:10.1038/nature10135)
34. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010 467 285-290. (doi:10.1038/nature09342)
35. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011 471 68-73. (doi:10.1038/nature09798)
36. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K et al. A more efficient method to generate integration-free human iPS cells. Nature Methods 2011 8 409-412. (doi:10.1038/nmeth.1591)
37. Meng F, Chen S, Miao Q, Zhou K, Lao Q, Zhang X, Guo W & Jiao J. Induction of fibroblasts to neurons through adenoviral gene delivery. Cell Research 2012 22 436-440. (doi:10.1038/cr.2011.185)
38. Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, Muotri AR, Chi NC, Fu XD, Yu BD et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 2013 13 246-254. (doi:10.1016/j.stem.2013.06.001)
39. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A et al. Highly efficient reprogram-ming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010 7 618-630. (doi:10.1016/j.stem.2010.08.012)
40. Mandal PK & Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nature Protocols 2013 8 568-582. (doi:10.1038/nprot.2013.019)
41. Kim D, Kim C-H, Moon J-I, Chung Y-G, Chang M-Y, Han B-S, Ko S, Yang E, Cha KY, Lanza R et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009 4 472-476. (doi:10.1016/j.stem.2009.05.005)
42. Yusa K, Rad R, Takeda J & Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nature Methods 2009 6 363-369. (doi:10.1038/nmeth.1323)
43. Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka S & Miura K. Steps toward safe cell therapy using induced pluripotent stem cells. Circulation Research 2013 112 523-533. (doi:10.1161/CIRCRESAHA.111.256149)
44. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA & Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 2012 11 147-152. (doi:10.1016/j.stem.2012.07.014)
45. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, Wen Y, Rapp JA & Kessler J. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. Journal of the American Medical Association 2008 299 925-936. (doi:10.1001/jama. 299.8.925)
46. Ianus A, Holz GG, Theise ND & Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. Journal of Clinical Investigation 2003 111 843-850. (doi:10.1172/JCI200316502)
47. Hasegawa Y, Ogihara T, Yamada T, Ishigaki Y, Imai J, Uno K, Gao J, Kaneko K, Ishihara H, Sasano H et al. Bone marrow (BM) transplantation promotes b-cell regeneration after acute injury through BM cell mobilization. Endocrinology 2007 148 2006-2015. (doi:10.1210/en.2006-1351)
48. Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, Thyssen S, Gray DA & Bhatia M. Bone marrow-derived stem cells initiate pancreatic regeneration. Nature Biotechnology 2003 21 763-770. (doi:10.1038/nbt841)
49. Chen L-B, Jiang X-B & Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet b-cells. World Journal of Gastroenterology 2004 10 3016-3020.
50. Wu X-H, Liu C-P, Xu K-F, Mao X-D, Zhu J, Jiang J-J, Cui D, Zhang M, Xu Y & Liu C. Reversal of hyperglycemia in diabetic rats by portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem cells. World Journal of Gastroenterology 2007 13 3342-3349. (doi:10.1155/2014/757461)
51. Chao KC, Chao KF, Fu YS & Liu SH. Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes. PLoS ONE 2008 3 e1451. (doi:10.1371/journal.pone.0001451)
52. Lin H-Y, Tsai C-C, Chen L-L, Chiou S-H, Wang Y-J & Hung S-C. Fibronectin and laminin promote differentiation of human mesenchymal stem cells into insulin producing cells through activating Akt and ERK. Journal of Biomedical Science 2010 17 56. (doi:10.1186/1423-0127-17-56)
53. Pournasr B, Khaloughi K, Salekdeh GH, Totonchi M, Shahbazi E & Baharvand H. Concise review: alchemy of biology: generating desired cell types from abundant and accessible cells. Stem Cells 2011 29 1933-1941. (doi:10.1002/stem.760)
54. Hickey RD, Galivo F, Schug J, Brehm MA, Haft A, Wang Y, Benedetti E, Gu G, Magnuson MA, Shultz LD et al. Generation of islet-like cells from mouse gall bladder by direct ex vivo reprogramming. Stem Cell Research 2013 11 503-515. (doi:10.1016/j.scr.2013.02.005)
55. Mauda-Havakuk M, Litichever N, Chernichovski E, Nakar O, Winkler E, Mazkereth R, Orenstein A, Bar-Meir E, Ravassard P, Meivar-Levy I et al. Ectopic PDX-1 expression directly reprograms human keratinocytes along pancreatic insulin-producing cells fate. PLoS ONE 2011 6 e26298. (doi:10.1371/journal.pone.0026298)
56. Watada H, Kajimoto Y, Miyagawa J, Hanafusa T, Hamaguchi K, Matsuoka T, Yamamoto K, Matsuzawa Y, Kawamori R & Yamasaki Y. PDX-1 induces insulin and glucokinase gene expressions in aTC1 clone 6 cells in the presence of betacellulin. Diabetes 1996 45 1826-1831. (doi:10.2337/diab.45.12.1826)
57. Serup P, Jensen J, Andersen FG, Jorgensen MC, Blume N, Holst JJ & Madsen OD. Induction of insulin and islet amyloid polypeptide production in pancreatic islet glucagonoma cells by insulin promoter factor 1. PNAS 1996 93 9015-9020. (doi:10.1073/pnas.93.17.9015)
58. Ber I, Shternhall K, Perl S, Ohanuna Z, Goldberg I, Barshack I, Benvenisti-Zarum L, Meivar-Levy I & Ferber S. Functional, persistent, and extended liver to pancreas transdifferentiation. Journal of Biological Chemistry 2003 278 31950-31957. (doi:10.1074/jbc. M303127200)
59. Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seijffers R, Kopolovic J, Kaiser N et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nature Medicine 2000 6 568-572. (doi:10.1038/75050)
60. Pennarossa G, Maffei S, Campagnol M, Tarantini L, Gandolfi F & Brevini TA. Brief demethylation step allows the conversion of adult human skin fibroblasts into insulin-secreting cells. PNAS 2013 110 8948-8953. (doi:10.1073/pnas.1220637110)
61. Li K, Zhu S, Russ HA, Xu S, Xu T, Zhang Y, Ma T, Hebrok M & Ding S. Small molecules facilitate the reprogramming of mouse fibroblasts into pancreatic lineages. Cell Stem Cell 2014 14 228-236. (doi:10.1016/j.stem.2014.01.006)
62. Zhou Q, Brown J, Kanarek A, Rajagopal J & Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to b-cells. Nature 2008 455 627-632. (doi:10.1038/nature07314)
63. Banga A, Akinci E, Greder LV, Dutton JR & Slack JM. In vivo reprogramming of Sox9C cells in the liver to insulin-secreting ducts. PNAS 2012 109 15336-15341. (doi:10.1073/pnas.1201701109)
64. Dor Y, Brown J, Martinez OI & Melton DA. Adult pancreatic b-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004 429 41-46. (doi:10.1038/nature02520)
65. Nir T, Melton DA & Dor Y. Recovery from diabetes in mice by b cell regeneration. Journal of Clinical Investigation 2007 117 2553-2561. (doi:10.1172/JCI32959)
66. Teta M, Rankin MM, Long SY, Stein GM & Kushner JA. Growth and regeneration of adult b cells does not involve specialized progenitors. Developmental Cell 2007 12 817-826. (doi:10.1016/j.devcel.2007.04.011)
67. Talchai C, Xuan S, Lin HV, Sussel L & Accili D. Pancreatic b cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 2012 150 1223-1234. (doi:10.1016/j.cell.2012.07.029)
68. Xu X, D'Hoker J, Stange G, Bonne S, De Leu N, Xiao X, Van de Casteele M, Mellitzer G, Ling Z, Pipeleers D et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell 2008 132 197-207. (doi:10.1016/j.cell.2007.12.015)
69. Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, Billestrup N, Madsen OD, Serup P, Heimberg H & Mansouri A. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into a and subsequently b cells. Cell 2009 138 449-462. (doi:10.1016/j.cell.2009.05.035)
70. Thorel F, Nepote V, Avril I, Kohno K, Desgraz R, Chera S & Herrera PL. Conversion of adult pancreatic a-cells to b-cells after extreme b-cell loss. Nature 2010 464 1149-1154. (doi:10.1038/nature08894)
71. Yi P, Park JS & Melton DA. Betatrophin: a hormone that controls pancreatic b cell proliferation. Cell 2013 153 747-758. (doi:10.1016/j. cell.2013.04.008)
72. Jiao Y, Le Lay J, Yu M, Naji A & Kaestner KH. Elevated mouse hepatic betatrophin expression does not increase human b-cell replication in the transplant setting. Diabetes 2014 63 1283-1288. (doi:10.2337/db13-1435)
73. Gusarova V, Alexa CA, Na E, Stevis PE, Xin Y, Bonner-Weir S, Cohen JC, Hobbs HH, Murphy AJ, Yancopoulos GD et al. ANGPTL8/betatrophin does not control pancreatic b cell expansion. Cell 2014 159 691-696. (doi:10.1016/j.cell.2014.09.027)
74. Alvarez-Perez JC, Ernst S, Demirci C, Casinelli GP, Mellado-Gil JM, Rausell-Palamos F, Vasavada RC & Garcia-Ocana A. Hepatocyte growth factor/c-Met signaling is required for ss-cell regeneration. Diabetes 2014 63 216-223. (doi:10.2337/db13-0333)
75. Contreras JL, Eckstein C, Smyth CA, Sellers MT, Vilatoba M, Bilbao G, Rahemtulla FG, Young CJ, Thompson JA, Chaudry IH et al. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes 2003 52 2935-2942. (doi:10.2337/diabetes.52.12.2935)
76. Al-Adra DP, Gill RS, Imes S, O'Gorman D, Kin T, Axford SJ, Shi X, Senior PA & Shapiro AM. Single-donor islet transplantation and long-term insulin independence in select patients with type 1 diabetes mellitus. Transplantation 2014 98 1007-1012. (doi:10.1097/TP. 0000000000000217)
77. Matsumoto S, Noguchi H, Naziruddin B, Onaca N, Jackson A, Nobuyo H, Teru O, Naoya K, Klintmalm G & Levy M. Improvement of pancreatic islet cell isolation for transplantation. Proceedings (Baylor University. Medical Center) 2007 20 357-362.
78. Andres A, Kin T, O'Gorman D, Bigam D, Kneteman N, Senior P & Shapiro AJ. Impact of adverse pancreatic injury at surgical procurement upon islet isolation outcome. Transplant International 2014 27 1135-1142. (doi:10.1111/tri.12392)
79. Ahearn AJ, Parekh JR & Posselt AM. Islet transplantation for type 1 diabetes: where are we now? Expert Review of Clinical Immunology 2015 11 59-68. (doi:10.1586/1744666X.2015.978291)
80. Szot GL, Lee MR, Tavakol MM, Lang J, Dekovic F, Kerlan RK, Stock PG & Posselt AM. Successful clinical islet isolation using a GMP-manufactured collagenase and neutral protease. Transplantation 2009 88 753-756. (doi:10.1097/TP.0b013e3181b443ae)
81. Lakey JR, Aspinwall CA, Cavanagh TJ & Kennedy RT. Secretion from islets and single islet cells following cryopreservation. Cell Transplantation 1999 8 691-698.
82. Lakey JR, Warnock GL, Shapiro AM, Korbutt GS, Ao Z, Kneteman NM & Rajotte RV. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Transplantation 1999 8 285-292. (doi:10.1016/S0041-1345(97)01306-7)
83. Barbaro B, Salehi P, Wang Y, Qi M, Gangemi A, Kuechle J, Hansen MA, Romagnoli T, Avila J, Benedetti E et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation 2007 84 1200-1203. (doi:10.1097/01.tp.0000287127. 00377.6f)
84. Loganathan G, Dawra RK, Pugazhenthi S, Guo Z, Soltani SM, Wiseman A, Sanders MA, Papas KK, Velayutham K, Saluja AK et al. Insulin degradation by acinar cell proteases creates a dysfunctional environment for human islets before/after transplantation: benefits of a-1 antitrypsin treatment. Transplantation 2011 92 1222-1230. (doi:10.1097/TP.0b013e318237585c)
85. Rose NL, Palcic MM, Shapiro AM & Lakey JR. An evaluation of the activation of endogenous pancreatic enzymes during human islet isolations. Transplantation Proceedings 2003 35 2455-2457. (doi:10.1016/j.transproceed.2003.08.025)
86. Mwangi SM, Usta Y, Shahnavaz N, Joseph I, Avila J, Cano J, Chetty VK, Larsen CP, Sitaraman SV & Srinivasan S. Glial cell line-derived neurotrophic factor enhances human islet posttransplantation survival. Transplantation 2011 92 745-751. (doi:10.1097/TP. 0b013e31822bc95a)
87. Cabric S, Sanchez J, Lundgren T, Foss A, Felldin M, Kallen R, Salmela K, Tibell A, Tufveson G, Larsson R et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007 56 2008-2015. (doi:10.2337/db07-0358)
88. Farney AC, Xenos E, Sutherland DE, Widmer M, Stephanian E, Field MJ, Kaufman DB, Stevens RB, Blazar B, Platt J et al. Inhibition of pancreatic islet b cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplantation Proceedings 1993 25 865-866.
89. Yamamoto T, Mita A, Ricordi C, Messinger S, Miki A, Sakuma Y, Timoneri F, Barker S, Fornoni A, Molano RD et al. Prolactin supplementation to culture medium improves b-cell survival. Transplantation 2010 89 1328-1335. (doi:10.1097/TP. 0b013e3181d98af1)
90. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Current Diabetes Reports 2011 11 345-354. (doi:10.1007/s11892-011-0217-8)
91. Emamaullee JA & Shapiro AM. Interventional strategies to prevent b-cell apoptosis in islet transplantation. Diabetes 2006 55 1907-1914. (doi:10.2337/db05-1254)
92. Barshes NR, Wyllie S & Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. Journal of Leukocyte Biology 2005 77 587-597. (doi:10.1189/jlb.1104649)
93. Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M & Robbins PD. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1b-induced b-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999 48 1730-1736. (doi:10.2337/diabetes.48.9.1730)
94. Rink JS, Chen X, Zhang X & Kaufman DB. Conditional and specific inhibition of NF-kB in mouse pancreatic b cells prevents cytokine-induced deleterious effects and improves islet survival posttransplant. Surgery 2012 151 330-339. (doi:10.1016/j.surg.2011.07.011)
95. Gao Q, Ma LL, Gao X, Yan W, Williams P & Yin DP. TLR4 mediates early graft failure after intraportal islet transplantation. American Journal of Transplantation 2010 10 1588-1596. (doi:10.1111/j.1600-6143.2010.03151.x)
96. Bertera S, Crawford ML, Alexander AM, Papworth GD, Watkins SC, Robbins PD & Trucco M. Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. Diabetes 2003 52 387-393. (doi:10.2337/diabetes.52.2.387)
97. Li X, Chen H & Epstein PN. Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species. Journal of Biological Chemistry 2004 279 765-771. (doi:10.1074/jbc.M307907200)
98. Sklavos MM, Bertera S, Tse HM, Bottino R, He J, Beilke JN, Coulombe MG, Gill RG, Crapo JD, Trucco M et al. Redox modulation protects islets from transplant-related injury. Diabetes 2010 59 1731-1738. (doi:10.2337/db09-0588)
99. Brandhorst D, Brandhorst H, Zwolinski A, Nahidi F & Bretzel RG. Prevention of early islet graft failure by selective inducible nitric oxide synthase inhibitors after pig to nude rat intraportal islet transplantation. Transplantation 2001 71 179-184. (doi:10.1097/00007890-200101270-00002)
100. Gibly RF, Graham JG, Luo X, Lowe WL Jr, Hering BJ & Shea LD. Advancing islet transplantation: from engraftment to the immune response. Diabetologia 2011 54 2494-2505. (doi:10.1007/s00125-011-2243-0)
101. Pinkse GG, Bouwman WP, Jiawan-Lalai R, Terpstra OT, Bruijn JA & de Heer E. Integrin signaling via RGD peptides and anti-b1 antibodies confers resistance to apoptosis in islets of Langerhans. Diabetes 2006 55 312-317. (doi:10.2337/diabetes.55.02.06.db04-0195)
102. Jalili RB, Moeen Rezakhanlou A, Hosseini-Tabatabaei A, Ao Z, Warnock GL & Ghahary A. Fibroblast populated collagen matrix promotes islet survival and reduces the number of islets required for diabetes reversal. Journal of Cellular Physiology 2011 226 1813-1819. (doi:10.1002/jcp.22515)
103. Nilsson B, Ekdahl KN & Korsgren O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Current Opinion in Organ Transplantation 2011 16 620-626. (doi:10.1097/MOT.0b013e32834c2393)
104. Takahashi H, Goto M, Ogawa N, Saito Y, Fujimori K, Kurokawa Y, Doi H & Satomi S. Superiority of fresh islets compared with cultured islets. Transplantation Proceedings 2009 41 350-351. (doi:10.1016/j.transproceed.2008.08.143)
105. Moberg L, Olsson A, Berne C, Felldin M, Foss A, Kallen R, Salmela K, Tibell A, Tufveson G, Nilsson B et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation 2003 76 1285-1288. (doi:10.1097/01.TP.0000098905.86445.0F)
106. Berman DM, Cabrera O, Kenyon NM, Miller J, Tam SH, Khandekar VS, Picha KM, Soderman AR, Jordan RE, Bugelski PJ et al. Interference with tissue factor prolongs intrahepatic islet allograft survival in a non-human primate marginal mass model. Transplantation 2007 84 308-315. (doi:10.1097/01.tp.0000275401.80187.1e)
107. Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O & Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002 51 1779-1784. (doi:10.2337/diabetes. 51.6.1779)
108. Contreras JL, Eckstein C, Smyth CA, Bilbao G, Vilatoba M, Ringland SE, Young C, Thompson JA, Fernandez JA, Griffin JH et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 2004 53 2804-2814. (doi:10.2337/diabetes.53.11.2804)
109. Akima S, Hawthorne WJ, Favaloro E, Patel A, Blyth K, Mudaliar Y, Chapman JR & O'Connell PJ. Tirofiban and activated protein C synergistically inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from allogeneic islet cells exposure to human blood. American Journal of Transplantation 2009 9 1533-1540. (doi:10.1111/j.1600-6143.2009.02673.x)
110. Cui W, Angsana J, Wen J & Chaikof EL. Liposomal formulations of thrombomodulin increase engraftment after intraportal islet transplantation. Cell Transplantation 2010 19 1359-1367. (doi:10.3727/096368910X513964)
111. Cui W, Wilson JT, Wen J, Angsana J, Qu Z, Haller CA & Chaikof EL. Thrombomodulin improves early outcomes after intraportal islet transplantation. American Journal of Transplantation 2009 9 1308-1316. (doi:10.1111/j.1600-6143.2009.02652.x)
112. Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, Malcolm A, Toso C, Nilsson B, Korsgren O et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation 2010 89 465-471. (doi:10.1097/TP. 0b013e3181c478fd)
113. Goto M, Johansson H, Maeda A, Elgue G, Korsgren O & Nilsson B. Low-molecular weight dextran sulfate abrogates the instant blood-mediated inflammatory reaction induced by adult porcine islets both in vitro and in vivo. Transplantation Proceedings 2004 36 1186-1187. (doi:10.1016/j.transproceed.2004.04.028)
114. Wilson JT, Haller CA, Qu Z, Cui W, Urlam MK & Chaikof EL. Biomolecular surface engineering of pancreatic islets with thrombo-modulin. Acta Biomaterialia 2010 6 1895-1903. (doi:10.1016/j.actbio. 2010.01.027)
115. Luan NM, Teramura Y & Iwata H. Layer-by-layer co-immobilization of soluble complement receptor 1 and heparin on islets. Biomaterials 2011 32 6487-6492. (doi:10.1016/j.biomaterials.2011.05.048)
116. Luan NM, Teramura Y & Iwata H. Immobilization of the soluble domain of human complement receptor 1 on agarose-encapsulated islets for the prevention of complement activation. Biomaterials 2010 31 8847-8853. (doi:10.1016/j.biomaterials.2010.08.004)
117. Kim HI, Yu JE, Lee SY, Sul AY, Jang MS, Rashid MA, Park SG, Kim SJ, Park CG, Kim JH et al. The effect of composite pig islet-human endothelial cell grafts on the instant blood-mediated inflammatory reaction. Cell Transplantation 2009 18 31-37. (doi:10.3727/096368909788237113)
118. Cantley J, Grey ST, Maxwell PH & Withers DJ. The hypoxia response pathway and b-cell function. Diabetes, Obesity & Metabolism 2010 12 (Suppl 2) 159-167. (doi:10.1111/j.1463-1326.2010.01276.x)
119. Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, Zhang H, Song K, Meseck M, Bromberg J et al. Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes 2004 53 963-970. (doi:10.2337/diabetes.53. 4.963)
120. Finetti F, Basile A, Capasso D, Di Gaetano S, Di Stasi R, Pascale M, Turco CM, Ziche M, Morbidelli L & D'Andrea LD. Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochemical Pharmacology 2012 84 303-311. (doi:10.1016/j.bcp.2012.04.011)
121. Cabric S, Sanchez J, Johansson U, Larsson R, Nilsson B, Korsgren O & Magnusson PU. Anchoring of vascular endothelial growth factor to surface-immobilized heparin on pancreatic islets: implications for stimulating islet angiogenesis. Tissue Engineering. Part A 2010 16 961-970. (doi:10.1089/ten.tea.2009.0429)
122. Olsson R, Maxhuni A & Carlsson PO. Revascularization of transplanted pancreatic islets following culture with stimulators of angiogenesis. Transplantation 2006 82 340-347. (doi:10.1097/01.tp. 0000229418.60236.87)
123. Luo L, Badiavas E, Luo JZ & Maizel A. Allogeneic bone marrow supports human islet b cell survival and function over six months. Biochemical and Biophysical Research Communications 2007 361 859-864. (doi:10.1016/j.bbrc.2007.07.105)
124. Song HJ, Xue WJ, Li Y, Tian XH, Ding XM, Feng XS, Song Y & Tian PX. Prolongation of islet graft survival using concomitant transplantation of islets and vascular endothelial cells in diabetic rats. Transplantation Proceedings 2010 42 2662-2665. (doi:10.1016/j.transproceed.2010. 06.003)
125. Cantaluppi V, Biancone L, Figliolini F, Beltramo S, Medica D, Deregibus MC, Galimi F, Romagnoli R, Salizzoni M, Tetta C et al. Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets. Cell Transplantation 2012 21 1305-1320. (doi:10.3727/096368911X627534)
126. Al-Khaldi A, Eliopoulos N, Martineau D, Lejeune L, Lachapelle K & Galipeau J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Therapy 2003 10 621-629. (doi:10.1038/sj.gt.3301934)
127. Barsotti MC, Magera A, Armani C, Chiellini F, Felice F, Dinucci D, Piras AM, Minnocci A, Solaro R, Soldani G et al. Fibrin acts as biomimetic niche inducing both differentiation and stem cell marker expression of early human endothelial progenitor cells. Cell Proliferation 2011 44 33-48. (doi:10.1111/j.1365-2184.2010.00715.x)
128. Sigrist S, Mechine-Neuville A, Mandes K, Calenda V, Legeay G, Bellocq JP, Pinget M & Kessler L. Induction of angiogenesis in omentum with vascular endothelial growth factor: influence on the viability of encapsulated rat pancreatic islets during transplantation. Journal of Vascular Research 2003 40 359-367. (doi:10.1159/000072700)
129. Davis GE & Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circulation Research 2005 97 1093-1107. (doi:10.1161/01.RES.0000191547.64391.e3)
130. Hiscox AM, Stone AL, Limesand S, Hoying JB & Williams SK. An islet-stabilizing implant constructed using a preformed vasculature. Tissue Engineering. Part A 2008 14 433-440. (doi:10.1089/tea.2007. 0099)
131. Dionne KE, Colton CK & Yarmush ML. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993 42 12-21. (doi:10.2337/diab.42.1.12)
132. Sakata N, Chan NK, Ostrowski RP, Chrisler J, Hayes P, Kim S, Obenaus A, Zhang JH & Hathout E. Hyperbaric oxygen therapy improves early posttransplant islet function. Pediatric Diabetes 2010 11 471-478. (doi:10.1111/j.1399-5448.2009.00629.x)
133. Ludwig B, Rotem A, Schmid J, Weir GC, Colton CK, Brendel MD, Neufeld T, Block NL, Yavriyants K, Steffen A et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. PNAS 2012 109 5022-5027. (doi:10.1073/pnas.1201868109)
134. Nadithe V, Mishra D & Bae YH. Poly(ethylene glycol) cross-linked hemoglobin with antioxidant enzymes protects pancreatic islets from hypoxic and free radical stress and extends islet functionality. Biotechnology and Bioengineering 2012 109 2392-2401. (doi:10.1002/bit.24501)
135. Pedraza E, Coronel MM, Fraker CA, Ricordi C & Stabler CL. Preventing hypoxia-induced cell death in b cells and islets via hydrolytically activated, oxygen-generating biomaterials. PNAS 2012 109 4245-4250. (doi:10.1073/pnas.1113560109)
136. Miao G, Ostrowski RP, Mace J, Hough J, Hopper A, Peverini R, Chinnock R, Zhang J & Hathout E. Dynamic production of hypoxia-inducible factor-1a in early transplanted islets. American Journal of Transplantation 2006 6 2636-2643. (doi:10.1111/j.1600-6143.2006. 01541.x)
137. Papas KK, Avgoustiniatos ES, Tempelman LA, Weir GC, Colton CK, Pisania A, Rappel MJ, Friberg AS, Bauer AC & Hering BJ. High-density culture of human islets on top of silicone rubber membranes. Transplantation Proceedings 2005 37 3412-3414. (doi:10.1016/j.trans-proceed.2005.09.086)
138. Simoni J, Villanueva-Meyer J, Simoni G, Moeller JF & Wesson DE. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system. Artificial Organs 2009 33 115-126. (doi:10.1111/j.1525-1594.2008. 00695.x)
139. Spiess BD. Perfluorocarbon emulsions as a promising technology: a review of tissue and vascular gas dynamics. Journal of Applied Physiology 2009 106 1444-1452. (doi:10.1152/japplphysiol.90995.2008)
140. Maillard E, Juszczak MT, Langlois A, Kleiss C, Sencier MC, Bietiger W, Sanchez-Dominguez M, Krafft MP, Johnson PR, Pinget M et al. Perfluorocarbon emulsions prevent hypoxia of pancreatic b-cells. Cell Transplantation 2012 21 657-669. (doi:10.3727/096368911X593136)
141. Riess JG. Fluorocarbon-based oxygen carriers: new orientations. Artificial Organs 1991 15 408-413.
142. Maillard E, Juszczak MT, Clark A, Hughes SJ, Gray DR & Johnson PR. Perfluorodecalin-enriched fibrin matrix for human islet culture. Biomaterials 2011 32 9282-9289. (doi:10.1016/j.biomaterials.2011. 08.044)
143. Oluwole OO, Depaz HA, Gopinathan R, Ali A, Garrovillo M, Jin MX, Hardy MA & Oluwole SF. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific permanent acceptance of rat islets by adoptive transfer of allopeptide-pulsed host myeloid and thymic dendritic cells. Diabetes 2001 50 1546-1552. (doi:10.2337/diabetes.50.7.1546)
144. Britt LD, Scharp DW, Lacy PE & Slavin S. Transplantation of islet cells across major histocompatibility barriers after total lymphoid irradiation and infusion of allogeneic bone marrow cells. Diabetes 1982 31 (Suppl 4) 63-68. (doi:10.2337/diab.31.4.S63)
145. Li H, Kaufman CL, Boggs SS, Johnson PC, Patrene KD & Ildstad ST. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. Journal of Immunology 1996 156 380-388.
146. Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN & Sykes M. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 2004 53 376-383. (doi:10.2337/diabetes.53.2.376)
147. Morelli AE & Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nature Reviews. Immunology 2007 7 610-621. (doi:10.1038/nri2132)
148. Giannoukakis N, Phillips B, Finegold D, Harnaha J & Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011 34 2026-2032. (doi:10.2337/dc11-0472)
149. Liang X, Lu L, Chen Z, Vickers T, Zhang H, Fung JJ & Qian S. Administration of dendritic cells transduced with antisense oligo-deoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation 2003 76 721-729. (doi:10.1097/01.TP. 0000076470.35404.49)
150. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H & Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998 66 1567-1574. (doi:10.1097/00007890-199812270-00001)
151. Lee WC, Zhong C, Qian S, Wan Y, Gauldie J, Mi Z, Robbins PD, Thomson AW & Lu L. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-b. Transplantation 1998 66 1810-1817. (doi:10.1097/00007890-199812270-00040)
152. Ferreira GB, van Etten E, Verstuyf A, Waer M, Overbergh L, Gysemans C & Mathieu C. 25-dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes/Metabolism Research and Reviews 2011 27 933-941. (doi:10.1002/dmrr.1275)
153. da Costa TB, Sardinha LR, Larocca R, Peron JP & Rizzo LV. Allogeneic apoptotic thymocyte-stimulated dendritic cells expand functional regulatory T cells. Immunology 2011 133 123-132. (doi:10.1111/j. 1365-2567.2011.03420.x)
154. Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD Jr & Thomson AW. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 2003 101 611-620. (doi:10.1182/blood-2002-06-1769)
155. Thery C, Zitvogel L & Amigorena S. Exosomes: composition, biogenesis and function. Nature Reviews. Immunology 2002 2 569-579. (doi:10.1038/nri855)
156. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K & Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews 2006 212 28-50. (doi:10.1111/j.0105-2896.2006.00420.x)
157. Gagliani N, Jofra T, Stabilini A, Valle A, Atkinson M, Roncarolo MG & Battaglia M. Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes 2010 59 433-439. (doi:10.2337/db09-1168)
158. C regulatory T cells from nonobese diabetic mice. Journal of Immunology 2005 175 3053-3059. (doi:10.4049/jimmunol. 175.5.3053)
159. C T cells into alloantigen-specific and allograft protective Foxp3C regulatory T cells. Transplantation 2012 93 580-588.
160. Pothoven KL, Kheradmand T, Yang Q, Houlihan JL, Zhang H, Degutes M, Miller SD & Luo X. Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-b1 for islet transplantation. American Journal of Transplantation 2010 10 1774-1784. (doi:10.1111/j.1600-6143.2010.03199.x)
161. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E & Roncarolo MG. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006 55 40-49. (doi:10.2337/diabetes.55.01.06.db05-0613)
162. Marek N, Krzystyniak A, Ergenc I, Cochet O, Misawa R, Wang LJ, Golab K, Wang X, Kilimnik G, Hara M et al. Coating human pancreatic islets with CD4(C)CD25(high)CD127(K) regulatory T cells as a novel approach for the local immunoprotection. Annals of Surgery 2011 254 512-518 discussion 518-519. (doi:10.1097/SLA.0b013e31822c9ca7)
163. Montane J, Bischoff L, Soukhatcheva G, Dai DL, Hardenberg G, Levings MK, Orban PC, Kieffer TJ, Tan R & Verchere CB. Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. Journal of Clinical Investigation 2011 121 3024-3028. (doi:10.1172/JCI43048)
164. Lee KM, Stott RT, Zhao G, SooHoo J, Xiong W, Lian MM, Fitzgerald L, Shi S, Akrawi E, Lei J et al. TGF-b-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. European Journal of Immunology 2014 44 1728-1736. (doi:10.1002/eji. 201344062)
165. Lee K, Nguyen V, Lee KM, Kang SM & Tang Q. Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. American Journal of Transplantation 2014 14 27-38. (doi:10.1111/ajt.12509)
166. Li FR, Wang XG, Deng CY, Qi H, Ren LL & Zhou HX. Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clinical and Experimental Immunology 2010 161 357-363. (doi:10.1111/j.1365-2249.2010.04178.x)
167. Solari MG, Srinivasan S, Boumaza I, Unadkat J, Harb G, Garcia-Ocana A & Feili-Hariri M. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. Journal of Autoimmunity 2009 32 116-124. (doi:10.1016/j.jaut.2009.01.003)
168. Berman DM, Willman MA, Han D, Kleiner G, Kenyon NM, Cabrera O, Karl JA, Wiseman RW, O'Connor DH, Bartholomew AM et al. Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes 2010 59 2558-2568. (doi:10.2337/db10-0136)
169. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ & Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metallo-proteinase-2 and-9. Diabetes 2009 58 1797-1806. (doi:10.2337/db09-0317)
170. Longoni B, Szilagyi E, Quaranta P, Paoli GT, Tripodi S, Urbani S, Mazzanti B, Rossi B, Fanci R, Demontis GC et al. Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technology & Therapeutics 2010 12 435-446. (doi:10.1089/dia.2009.0154)
171. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosup-pressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 2010 90 1595-1601. (doi:10.1097/TP. 0b013e3181fe1377)
172. Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, Law K, Schuetz C, Carvello M, Orsenigo E et al. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 2010 59 2253-2264. (doi:10.2337/db09-1264)
173. Wang X, Hao J, Metzger DL, Mui A, Lee IF, Akhoundsadegh N, Ao Z, Chen L, Ou D, Verchere CB et al. Endogenous expression of B7-H4 improves long-term murine islet allograft survival. Transplantation 2013 95 94-99. (doi:10.1097/TP.0b013e318277229d)
174. Wang X, Hao J, Metzger DL, Mui A, Ao Z, Verchere CB, Chen L, Ou D & Warnock GL. Local expression of B7-H4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival. Transplantation 2009 87 482-490. (doi:10.1097/TP.0b013e318195e5fa)
175. Nanji SA, Hancock WW, Anderson CC, Adams AB, Luo B, Schur CD, Pawlick RL, Wang L, Coyle AJ, Larsen CP et al. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. American Journal of Transplantation 2004 4 526-536. (doi:10.1111/j.1600-6143. 2004.00384.x)
176. Abdi R, Means TK & Luster AD. Chemokines in islet allograft rejection. Diabetes/Metabolism Research and Reviews 2003 19 186-190. (doi:10.1002/dmrr.362)
177. Citro A, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, Dugnani E, Sordi V, Magistretti P, Daffonchio L et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. Journal of Clinical Investigation 2012 122 3647-3651. (doi:10.1172/JCI63089)
178. de Vos P & Marchetti P. Encapsulation of pancreatic islets for transplantation in diabetes: the untouchable islets. Trends in Molecular Medicine 2002 8 363-366. (doi:10.1016/S1471-4914(02)02381-X)
179. O'Sullivan ES, Vegas A, Anderson DG & Weir GC. Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocrine Reviews 2011 32 827-844. (doi:10.1210/er.2010-0026)
180. Teramura Y & Iwata H. Bioartificial pancreas microencapsulation and conformal coating of islet of Langerhans. Advanced Drug Delivery Reviews 2010 62 827-840. (doi:10.1016/j.addr.2010.01.005)
181. Lacy PE, Hegre OD, Gerasimidi-Vazeou A, Gentile FT & Dionne KE. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science 1991 254 1782-1784. (doi:10.1126/science.1763328)
182. Sakata N, Sumi S, Gu Y, Qi M, Yamamoto C, Sunamura M, Egawa S, Unno M, Matsuno S & Inoue K. Hyperglycemia and diabetic renal change in a model of polyvinyl alcohol bioartificial pancreas transplantation. Pancreas 2007 34 458-465. (doi:10.1097/MPA. 0b013e318040d0cd)
183. Ludwig B, Reichel A, Steffen A, Zimerman B, Schally AV, Block NL, Colton CK, Ludwig S, Kersting S & Bonifacio E. Transplantation of human islets without immunosuppression. PNAS 2013 110 19054-19058. (doi:10.1073/pnas.1317561110)
184. Bisikirska B, Colgan J, Luban J, Bluestone JA & Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8CT cell population and induces CD8CCD25C Tregs. Journal of Clinical Investigation 2005 115 2904-2913. (doi:10.1172/JCI23961)
185. Toso C, Edgar R, Pawlick R, Emamaullee J, Merani S, Dinyari P, Mueller TF, Shapiro AM & Anderson CC. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transplant International 2009 22 182-191. (doi:10.1111/j.1432-2277.2008.00746.x)
186. C regulatory T cells. Clinical Immunology 2006 120 247-259. (doi:10.1016/j.clim.2006. 05.006)
187. Rabinovitch A, Sumoski W, Rajotte RV & Warnock GL. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. Journal of Clinical Endocrinology and Metabolism 1990 71 152-156. (doi:10.1210/jcem-71-1-152)
188. C T cell levels in NOD mice. PNAS 2002 99 12287-12292. (doi:10.1073/pnas.172382999)
189. Froud T, Baidal DA, Ponte G, Ferreira JV, Ricordi C & Alejandro R. Resolution of neurotoxicity and b-cell toxicity in an islet transplant recipient following substitution of tacrolimus with MMF. Cell Transplantation 2006 15 613-620. (doi:10.3727/000000006783981639)
190. Johnson JD, Ao Z, Ao P, Li H, Dai LJ, He Z, Tee M, Potter KJ, Klimek AM, Meloche RM et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplantation 2009 18 833-845. (doi:10.3727/096368909X471198)
191. Bluestone JA. CTLA-4Ig is finally making it: a personal perspective. American Journal of Transplantation 2005 5 423-424. (doi:10.1111/j. 1600-6143.2005.00786.x)
192. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. American Journal of Transplantation 2010 10 1870-1880. (doi:10.1111/j.1600-6143.2010.03073.x)
193. Shapiro AM, Gallant HL, Hao EG, Lakey JR, McCready T, Rajotte RV, Yatscoff RW & Kneteman NM. The portal immunosuppressive storm: relevance to islet transplantation? Therapeutic Drug Monitoring 2005 27 35-37. (doi:10.1097/00007691-200502000-00008)